Skip to content

Nuvation Bio NUVB Other income, net (Note 6)

Other income, net (Note 6) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$32M+90.6%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$186K+15.8%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$1.08M+0.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$336K-226%
Pfizer logo
PfizerPFE
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's other income, net (note 6)?
Nuvation Bio (NUVB) reported other income, net (note 6) of $562.75K in Q4 2025.
How has Nuvation Bio's other income, net (note 6) changed year-over-year?
Nuvation Bio's other income, net (note 6) increased by 2165.1% year-over-year, from -$27.25K to $562.75K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.